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Simple Summary: Malignant pleural mesothelioma (MPM) is a rare cancer with an aggressive
disease course. For patients who are medically inoperable or surgically unresectable, multi-agent
systemic therapy remains an accepted standard-of-care around the world. Given the rare incidence of
MPM and the disease’s aggressive nature, novel clinical trial designs are required. The purpose of this
meta-analysis is to provide baseline summative survival estimates as well as evaluate the influence
of prognostic variables to provide comparative estimates for future trial designs. In this study, a
nomogram model was created to estimate survival with treatment with platinum-pemetrexed using
covariates known to be associated with survival, including median age, gender, ECOG performance
status, tumor stage, and tumor pathology subtype. Collaborative efforts can drive the change in the
right direction, and appreciable progress has to be facilitated and newer trial designs may need to
pave the way for future innovations in this rare disease.
Abstract: (1) Purpose: Malignant pleural mesothelioma (MPM) is a rare cancer with an aggressive
course. For patients who are medically inoperable or surgically unresectable, multi-agent systemic
chemotherapy remains an accepted standard-of-care. The purpose of this meta-analysis is to provide
baseline summative survival estimates as well as evaluate the influence of prognostic variables to
provide comparative estimates for future trial designs. (2) Methods: Using PRISMA guidelines, a
systematic review and meta-analysis was performed of MPM studies published from 2002–2019
obtained from the Medline database evaluating systemic therapy combinations for locally advanced
or metastatic disease. Weighted random effects models were used to calculate survival estimates. The
influence of proportions of known prognostic factors on overall survival (OS) were evaluated in the
creation of a prognostic nomogram to estimate survival. The performance of this model was evaluated
against data generated from one positive phase II study and two positive randomized trials. (3)
Results: Twenty-four phase II studies and five phase III trials met the eligibility criteria; 2534 patients
were treated on the included clinical studies. Ten trials included a platinum-pemetrexed-based
treatment regimen, resulting in a pooled estimate of progression-free survival (PFS) of 6.7 months
(95% CI: 6.2–7.2 months) and OS of 14.2 months (95% CI: 12.7–15.9 months). Fifteen experimental
chemotherapy regimens have been tested in phase II or III studies, with a pooled median survival
estimate of 13.5 months (95% CI: 12.6–14.6 months). Meta-regression analysis was used to estimate
OS with platinum-pemetrexed using a variety of features, such as pathology (biphasic vs. epithelioid),
disease extent (locally advanced vs. metastatic), ECOG performance status, age, and gender. The
nomogram-predicted estimates and corresponding 95% CIs performed well when applied to recent
randomized studies. (4) Conclusions: Given the rarity of MPM and the aggressive nature of the
disease, innovative clinical trial designs with significantly greater randomization to experimental
Cancers 2021, 13, 2186. https://doi.org/10.3390/cancers13092186 https://www.mdpi.com/journal/cancers
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regimens can be performed using robust survival estimates from prior studies. This study provides
baseline comparative values and also allows for accounting for differing proportions of known
prognostic variables.
Keywords: mesothelioma; first line; meta-analysis; systematic review
1. Introduction
Malignant pleural mesothelioma (MPM) is a rare cancer with an aggressive disease
course associated with poor prognosis [1]. Its incidence in the United States is approxi-
mately 3000 new cases diagnosed annually, but is still increasing in the rest of the world,
particularly Asia and Europe [2]. Due to its insidious presentation, most patients are
diagnosed with locally advanced or metastatic disease-unamenable to radical resection.
For patients who are medically inoperable or surgically unresectable, multi-agent systemic
chemotherapy remains a current standard-of-care with a median survival of approximately
12 months [3].
Although recent data from the CheckMate 743 trial have demonstrated improved
outcomes with first-line immunotherapy [4], the combination of cisplatin and pemetrexed
is commonly utilized in the front-line setting worldwide [5,6]. Carboplatin has similar
efficacy to cisplatin, with a favorable toxicity profile and ease of administration; therefore,
it has often been used in combination with pemetrexed for a large proportion of MPM
patients, especially the elderly [7]. The purpose of this meta-analysis is to provide baseline
summative survival estimates as well as evaluate the influence of basic prognostic variables
to provide comparative estimates for future trial designs.
2. Methods
2.1. Selection of Articles
The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
criteria were followed in conducting this systematic review and meta-analysis [8]. The arti-
cle selection was performed by searching the MEDLINE (PubMed) and Cochrane electronic
bibliographic databases for first-line systemic therapy combinations for patients with locally
advanced or metastatic MPM. To ensure a comprehensive initial search strategy, generic
key words were used in the initial article screen: “mesothelioma” and “locally advanced”
and “metastatic” and “first-line” and “systemic therapies” and “platinum/pemetrexed”
and “experimental therapies”. Full text articles published in the English language were
considered and no publishing date restrictions were used through February 2021.
The initial query identified 447 reports that were subsequently screened by thorough
review of the article titles and abstracts, as necessary. Inclusion criteria were publication
in the English language, phase II and phase III clinical trials with 10 or more patients
evaluable and with published outcomes on the efficacy endpoints of interest. Publications
that were available in abstract only form and those in languages other than English were
excluded. Case reports and limited case series, preclinical trials, studies using locoregional
interventions alone, and studies using second-line therapies, were all excluded. A manual
review of the references of the articles that were retrieved was performed to identify
additional relevant publications. The search strategy used for this meta-analysis and the
methodology for study inclusion is illustrated in Figure S1.
The studies were divided by treatment regimen: platinum-pemetrexed-based treat-
ment and other experimental therapies. The demographic data abstracted for this analysis
included year of publication, acronyms of the study or study title, duration of the study
period, type of study (phase II/III), primary and secondary endpoints, number of patients
included, median age, sex (male/female), ECOG Performance status (0,1,2), tumor stage
(loco-regional disease; stage I–III and metastatic disease; stage IV), and tumor pathology
(epithelioid, biphasic, sarcomatoid). Overall survival (OS), 1-year and 2-year OS rates,
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progression free survival (PFS), and objective response rate (ORR) were the outcomes
evaluated. The radiological response data included patients having complete response
(CR), partial response (PR), stable disease (SD), progressive disease (PD), and disease
control rate (DCR). The toxicity summary included patients with grade 3–4 toxicities and
was subdivided into toxicity category (i.e., general, blood and lymphatic system, cardiac,
gastro-intestinal, infections, respiratory, and skin).
2.2. Outcome Measures and Statistical Analysis
The primary outcomes were OS and PFS; extracted medians of these variables were
transferred into a logarithm scale [9]. The random-effects model described by DerSimonian
and Laird [10] was used for this analysis. For primary and secondary outcomes, corre-
sponding forest plots were created. Study heterogeneity was assessed using I2 statistics.
Values of 0–30%, 31–60%, 61–75%, and 76–100% indicated low, moderate, substantial, or
considerable heterogeneity, respectively [11]. All analyses were performed in R (Version 4.0,
R Foundation for Statistical Computing, Vienna, Austria). For identifying publication bias,
funnel plots and the Egger test were used. Statistical significance of p < 0.05 indicated the
presence of bias. To investigate the potential effects of each of the prognostic variables on
OS, patient characteristics were also extracted from each study and included as predictors
in the meta-regression model. Considered variables include median age, gender, ECOG
performance status, tumor stage, and tumor pathology. The extent to which the meta-
regression model explained heterogeneity of the effect among studies was quantified by the
percentage reduction of between-study variability. Plot of residuals was used to check the
adequacy of the meta-regression model. Nomograms were used to represent results of the
meta-regression model, estimating survival time using the covariates. In developing the
nomogram, we used model coefficients to assign points to characteristics and predictions
from the model to map cumulative point totals. Finally, the nomogram was used to predict
the overall survival outcomes reported in the positive phase II reports (STELLAR [12]
study) and phase III studies (MAPS [13] and CheckMate 743 [4]) and compared to the
original results to assess the model performance.
3. Results
Twenty-four phase II studies and five phase III trials were included in this meta-
analysis with outcomes data collected on 2534 patients (Figure S1). Key patient charac-
teristics, demographics, and treatment information were not uniformly or consistently
reported across the literature. However, there was no publication bias detected (p > 0.05)
across the included studies regarding the primary outcomes evaluated in this meta-analysis
(Figure S2).
3.1. Demographic Data of Platinum-Pemetrexed Regimen
Ten trials (n = 1303 patients) included a platinum-pemetrexed-based treatment regimen
with a median of 89 patients in each study (range: 11–302 patients) (Table 1). Across all
studies, 81% were male, and the median age was 66 years (range: 59–72 years). The majority
of patients (60%) had an ECOG status of 1. The patients diagnosed with loco-regional disease
and metastatic disease were 35% and 47%, respectively. The majority of patients across all
studies were epithelioid (80%), followed by biphasic (11%), and sarcomatoid (8%).
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Table 1. Demographic data of malignant pleural mesothelioma patients treated with cisplatin/carboplatin and pemetrexed.









Sex [No.(%)] ECOG Performance Status [No.(%)] Tumour Stage Tumour Pathology
Male Female 0 1 2
Loco-Regional
(Stage I–III) Metastatic(Stage IV) Epithelioid Biphasic Sarcomatoid




of response 226 61
184
(81%) 42 (19%) NA NA NA 73 (32%) 102 (45%) 154 (68%) 37 (16%) 18 (8%)




OS 102 65 76 (75%) 26 (25%) 33 (32%) 61 (60%)
8
(8%) 34 (33%) 49 (48%) 80 (78%) 8 (8%) 7 (7%)
Castagneto et al. [14] 2008 NA 2003–2005 II
Carboplatin +
Pemetrexed RR OS, TTP, Toxicity 76 65 54 (71%) 22 (29%) NA NA NA 27 (36%) 36 (48%) 57 (75%) 13 (17%) 3 (4%)
Katirtzoglou et al. [15] 2010 NA 2004–2007 II
Carboplatin +
Pemetrexed RR OS, TTP 62 66 53 (86%) 9 (14%) 25 (40%) 37 (60%) 0 23 (37%) 17 (27%) 47 (76%) NA 15 (24%)
Krug et al. [16] 2014 NA NA II Cisplatin +Pemetrexed PFS
OS, DCR, and
safety/toxicity 23 66 20 (87%) 3 (13%) 7 (30%) 16 (70%) 0 NA NA 16 (70%) 2 (9%) 11 (18%)
Buikhuisen et al. [17] 2016 NA 2009–2012 II
Cisplatin +
Pemetrexed RR OS, PFS 11 59 10 (89%) 1 (11%) NA NA NA NA NA 10 (89%) 1 (11%) 0




(76%) 55 (25%) NA NA NA NA NA 182 (81%) NA NA




safety/toxicity 47 72 40 (85%) 7 (15%) NA NA NA NA NA 35 (74%) 12 (26%) NA






(74%) 60 (26%) 98 (43%)
131
(57%) NA 90 (39%) 105 (46%) 223 (97%) 6 (3%) NA
Baas et al. [4] 2021 CheckMate 743 2016–2018 III
Cisplatin/Carboplatin
+ Pemetrexed OS PFS, ORR, DCR 302 69
233
(77%) 69 (23%) 124 (42%)
173
(57%) NA 106 (35%) 149 (49%) 227 (75%) 39 (13%) 36 (12%)
Abbreviations: OS = overall survival; PFS = progression free survival; ORR = objective response rate; RR = response rate; TTP = time to progression; DCR = disease control rate; QoL = quality of life,
ECOG = Eastern Cooperative Oncology Group; NA = not available.
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3.2. Treatment Outcomes, Radiological Response, and Toxicity Summary Data of
Platinum-Pemetrexed Regimen
Treatment with a platinum-pemetrexed-based regimen resulted in a pooled PFS
of 6.7 months (95% CI: 6.2–7.2 months) and an OS of 14.2 months (95% CI: 12.7–15.9)
(Figure 1A,B).
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Across all studies, the proportion of ORR as 24 (95 CI: 12–35 ) and CR as
73% (95% CI: 56–90%) (Table 2). Across all patients, the proportion of individual response
rates for as 1.5 (95% CI: 1–4%), 19% PR (95% CI: 10–27%), 53% SD (95% CI: 37–69%),
and 31% PD (95% CI: 14–48%).
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et al. [6] 2003 226 12.1 6 NA 5.7 41.3 NA NA NA NA NA
11
(5%) NA NA NA NA NA 11 (5%) NA 3 (1%) 33 (15%)
Ceresoli
et al. [7] 2006 102 12.7 6.5 NA 6.5 19 2 (2%) 17 (17%)
48
(47%) 33 (33%) 67
12
(12%) 20 (20%) 8 (8%) NA 3 (3%) 1 (1%) NA NA NA 1 (1%)
Castagneto
et al. [14] 2008 76 14 NA NA 6 25 3 (4%) 16 (21%)
29
(38%) 28 (37%) 63 6 (8%) 25 (33%) 10 (13%) NA 9 (12%) NA 4 (5%) NA NA NA
Katirtzoglou
et al. [15] 2010 62 14 NA NA 7 29 0 18 (29%)
34
(56%) 10 (16%) 85
6
(10%) 15 (24%) 5 (8%) NA 2 (3%) 8 (13%) 1 (1%) NA 3 (5%) 9 (15%)
Krug
et al. [16] 2014 23 12.8 NA NA 3.4 10 0 2 (10%)
10
(50%) 8 (40%) 60 1 (4%) 1 (4%) NA 1 (4%) 1 (4%) 3 (13%) NA NA NA 2 (9%)
Buikhuisen
et al. [17] 2016 11 18.5 NA NA 8.3 18 NA 2 (18%) 8 (73%) NA 91 0 1 (5%) 0 0 0 0 NA 0 NA 0
Zalcman
et al. [13] 2016 225 16.1 NA NA 7.3 NA NA NA NA NA NA
30
(13%) 100 (44%) 21 (9%) 2 (1%) 3 (1%) 28 (13%) 7 (3%) NA NA 18 (8%)
Tsao et al.
[18] 2019 47 8.5 NA NA 5.6 20 NA NA NA NA NA
7
(15%) 9 (20%) 2 (4%) 0 0 6 (13%) NAA NA NA 0
Scagliotti
et al. [19] 2019 229 16.1 NA NA 7 43 NA 98 (43%) NA NA 93
33
(14%) 54 (24%) NA NA 10 (4%) 17 (7%) 14 (6%) NA 1 (1%) 15 (7%)
Baas et al.
[4] 2021 302 14.1 8.1 3.8 7.2 43 0 129 (43%)
125
(41%) 14 (5%) 85
32
(11%) 43 (15%) 10 (3%) NA 3 (2%) 5 (2%) NA NA 0 13 (4%)
Abbreviations: OS = overall survival; PFS = progression free survival; yr. = year; ORR = objective response rate; QoL = quality of life; NA = not available; N = number.
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The pooled estimates of the treatment-related toxicity outcomes for patients who
received a platinum-pemetrexed regimen (Figure 2A-I) with grade 3–4 blood and lymphatic
system toxicities were anemia 10% (95% CI: 8–13%), neutropenia 22% (95% CI: 15–30%),
and thrombocytopenia 7% (95% CI: 5–10%). Cardiac toxicity was seen in 1% (95% CI: 0–3%),
gastro-intestinal toxicity in 3% (95% CI: 1–5%), fatigue in 6% (95% CI: 3–12%), infections
in 5% (95% CI: 3–6%), skin toxicity in 1% (95% CI: 0–3%), and nausea and vomiting in 6%
(95% CI: 3–10%).
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3.3. e ographic ata of Experi ental Regi ens
ineteen trials tested 15 experimental chemotherapy regimens (n = 1231 patients)
in negative phase II or III studies, with a median of 52 patients (range: 20–229 patients)
in each study (Table A1). Across these studies, 75% were male, and the medi n age was
63 years (range: 55–72 years). Patients had an ECOG status of 0 (30%), 1 (60%), and 2 (10 ).
ti t i it l i l i t t ti i
, r ti l . , t j it f ti ts e it eli i s t e (76 ),
f ll i i ,
3.4. tco es, adiological espo se, a d oxicity ary ata of xperi e tal egi e s
Treat ent ith these experi ental regi ens resulted in a pooled esti ate of PFS of
6.6 onths (95 I: 6.2–7.0 onths) and S of 13.5 onths (95 I: 12.6–14.6 onths)
(Figure 1C,D). Across all studies, the proportion of ORR was 31% (95% CI: 26–36%) and the
DCR was 76% (95% CI: 69–84%) (Table A2). Responses using these experimental therapies
were low: overall proportions for CR were 0.7% (95% CI: 0.3–1.6%), 29% PR (95% CI:
24–34%), 48% SD (95% CI: 42–55%), 22% PD (95% CI: 13–29%).
The pooled toxicity estimates for patients who received experimental chemotherapy
regimens (Figure 3A-I) resulted in blood and lymphatic system grade 3–4 toxicities, with
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anemia in 4% (95% CI: 2–7%), neutropenia in 21% (95% CI: 12–33%), and thrombocytopenia
in 12% (95% CI: 6–24%). Cardiac toxicity was seen in 4% (95% CI: 2–9%), gastro-intestinal
toxicity in 4% (95% CI: 2–7%), fatigue in 12% (95% CI: 10–15%), infections in 5% (95% CI:
3–7%), skin toxicity in 1% (95% CI: 0–3%), and nausea and vomiting in 9% (95% CI: 6–15%).
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3.5. Development of a Prognostic Nomogram o Estimate Survival
M ta-regression analysis was used to estimate sur ival with treatment with l tinum-
pemetrexed si c ri t s known to be associated with OS, including median age,
gender, ECOG performance stat s, tumor stage, and tumor pathology subtype (Figure 4).
Unlike the aforementioned experimental regimens, two randomized phase III trials
and one single-arm phase II trial have demonstrated promising outcomes in this dis-
ease entity. The Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS) [13]
evaluated cisplatin/pemetrexed/bevacizumab compared to cisplatin/pemetrexed, the
STELLAR trial [12] evaluated the use of tumor-treating fields (TTFields) in addition to
cisplatin/pemetrexed, and recently CheckMate 743 [4] evaluated nivolumab plus ipili-
mumab compared to cisplatin/carboplatin and pemetrexed. To evaluate the prognostic
nomogram developed in this study, we compared the estimated outcomes using the patient
populations enrolled onto these studies and the proportion of each of the covariates and
compared the nomogram estimates with the published results. For the MAPS study, given
the patient population in the experimental arm of the phase III study, the OS estimate
from the nomogram was 15.76 months (95% CI: 13.96–17.81 months) compared to the
reported 18.8 months in the study. Similarly, the OS estimate from the nomogram using
the CheckMate 743 trial was 13.65 months (95% CI: 11.41–16.33 months) compared to
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18.1 months reported in the experimental arm. Therefore, the results of the experimental
arms of these two studies were outside the confidence interval estimate based on historical
data and consistent with a positive outcome. For the STELLAR trial, the OS estimate
from the nomogram was 16.95 months (95% CI: 10.49–27.38 months) and given the wide
confidence interval, potentially could overlap with the 18.2 months reported in the study.




Figure 4. Nomogram model developed to predict overall survival (OS) in patients with malignant 
pleural mesothelioma treated with platinum/pemetrexed therapy. The mean log OS can be calcu-
lated by drawing a vertical line connecting the value of each variable with the point score at the 
top of the nomogram. The point scores for individual variables are then summed to get a total 
point score. This is then plotted along the total points line at the bottom of the nomogram. This 
line is projected to the mean log OS of the trial. Then the exponential of mean log OS is calculated 
to obtain the OS in months. 
Unlike the aforementioned experimental regimens, two randomized phase III trials 
and one single-arm phase II trial have demonstrated promising outcomes in this disease 
entity. The Mesothelioma Avastin Plus Pemetrexed-cisplatin Study (MAPS) [13] evalu-
ated cisplatin/pemetrexed/bevacizumab compared to cisplatin/pemetrexed, the STELLAR 
trial [12] evaluated the use of tumor-treating fields (TTFields) in addition to cispla-
tin/pemetrexed, and recently CheckMate 743 [4] evaluated nivolumab plus ipilimumab 
compared to cisplatin/carboplatin and pemetrexed. To evaluate the prognostic nomogram 
developed in this study, we compared the estimated outcomes using the patient popula-
tions enrolled onto these studies and the proportion of each of the covariates and com-
pared the nomogram estimates with the published results. For the MAPS study, given the 
patient population in the experimental arm of the phase III study, the OS estimate from 
the nomogram was 15.76 months (95% CI: 13.96–17.81 months) compared to the reported 
18.8 months in the study. Similarly, the OS estimate from the nomogram using the Check-
Mate 743 trial was 13.65 months (95% CI: 11.41–16.33 months) compared to 18.1 months 
reported in the experimental arm. Therefore, the results of the experimental arms of these 
two studies were outside the confidence interval estimate based on historical data and 
consistent with a positive outcome. For the STELLAR trial, the OS estimate from the nom-
ogram was 16.95 months (95% CI: 10.49–27.38 months) and given the wide confidence 
interval, potentially could overlap with the 18.2 months reported in the study.  
4. Discussion 
Since 2003, chemotherapy with cisplatin/carboplatin and pemetrexed has been a 
standard first-line therapy for the majority of newly diagnosed patients who have locally 
advanced and metastatic MPM [6]. Over the past 15 years, multiple studies have estab-
lished the outcomes for MPM patients treated with this regimen including single-arm 
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4. Discussion
Since 2003, chemotherapy with cisplatin/carboplatin and pemetrexed has been a stan-
dard first-line therapy for the majority of newly diagnosed patients who have locally ad-
vanced and metastatic MPM [6]. Over the past 15 years, multiple studies have established
the outcomes for MPM patients treated with this regimen including single-arm phase II
trials [7,14,15], the experimental arms of randomized trials compared to cisplatin alone [6],
and the control arms of randomized trials testing novel experimental regimens [4,13,17–20].
In total, 1303 patients have been treated with this regimen across 10 studies, the data of
which were abstracted in this systematic review and meta-analysis to determine pooled
estimates of a PFS of 6.7 months and an OS of 14.2 months. In fact, a similar number—1231
patients—have been treated with experimental regimens who showed no improved out-
comes compared to these historical estimates, underscoring the need for novel therapeutic
development in this space. Moreover, despite advances in this field with the addition of
bevacizumab and immunotherapy, doublet chemotherapy remains to be commonly used
in most parts of the world where mesothelioma incidence continues to rise. Although
the addition of bevacizumab to first-line chemotherapy has been added to the national
guidelines [13], this regimen has not received FDA approval. Moreover, in CheckMate 743,
nivolumab and ipilimumab were compared to pemetrexed-platinum, and although the OS
was extended in the experimental arm, subgroup analysis yielded important caveats [4].
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For example, for patients with epithelioid histologies (75% of those enrolled), the 12-month
OS rates were not as striking (66% vs. 69%). Similarly, for those patients with a PDL-1 < 1%,
the Kaplan-Meier curves crossed with longer follow-up, yielding an overall hazard ratio of
0.94. Hence, the role of first-line chemotherapy continues to be evaluated in ongoing trials.
Randomized controlled trials (RCTs) are deemed the gold standard of clinical re-
search [21]. Randomization is often recommended for endpoints with a higher risk of
confounding and selection bias, and it has been shown to improve the ability of phase
II results to accurately predict phase III success [22,23]. However, modifications to tradi-
tional randomized trial designs have been performed to improve their performance in
clinical practice. For example, the permuted block randomization has been widely used;
however, in this design, there exists a compromise between effective imbalance control
with a small block size and accurate allocation target with large block size [24]. Several
alternative randomization designs have been proposed, such as the maximal procedure,
brick tunnel randomization, and block urn designs [25–27]. However, for cancers such as
mesothelioma, there are several logistical constraints for patients with rare diseases, as well
as accrual/drop-out issues for those randomized to standard arms with known historically
poor outcomes. Therefore, in other similar rare disease entities with robust historical
survival estimates, there has been a resurgence in the consideration of alternative clinical
trial designs [28]. Bayesian randomized designs and multi-arm multi-stage designs are two
different approaches for improving reliability by using patient outcomes [29]. The Bayesian
design allocates a greater proportion of prospective patients to well-performing treatments,
whereas the multi-arm multi-stage designs use pre-specified stopping boundaries to dis-
continue novel treatments due to lack of efficacy. Although the Bayesian randomized
designs have been shown to be more effective than traditional RCTs in multi-arm studies,
their efficiency improvements in two-arm studies have been modest, especially if the rate
of accrual outpaces the event rate, since the latter is required to modified the “prior” in a
Bayesian concept [29]. Some studies examined the effects of phase II designs for binary
endpoints on subsequent phase III trials, and found that randomization is useful when in-
terstudy variability is high or there is a tendency to underestimate the control response [30].
Therefore, there is continued need to develop novel methods of clinical study and pooling
historical data may help in future with future trial designs.
Meta-regression, the technique used in this study to develop the nomogram, is often
used to assess the relationship between one or more covariates and a dependent variable.
Similar approaches can be performed with a meta-analysis alone; however the covariates
are at the level of the study rather than the level of the subject [31]. The differences that
we need to address as we transition from using primary study data to meta-analysis for
regression are similar to those for subgroup analyses. For example, in this meta-analysis,
using meta-regression, we identified variables that were associated with OS and developed
a nomogram to determine the influence of each of these on survival, including median
age, gender, ECOG performance status, tumor stage, and tumor pathology. Using the
nomogram, the overall survival was predicted as reported in the positive phase II and III
studies and compared to the original result reported in these studies.
In the MAPS study [13], the patient population in the experimental arm of the phase
III study showed an OS estimate from the nomogram to be 15.76 months (95% CI: 13.96–
17.81 months), as compared to the 18.8 months that was reported in the original study.
Similarly, for another phase III study (CheckMate 743) [4], the OS estimate from the
nomogram was 13.65 months (95% CI: 11.41–16.33 months), as compared to 18.1 months
reported in the study. Based on the nomogram model developed from historical estimates,
the OS reported for the positive phase III trials are outside of the 95% confidence interval
range of the historical estimates; however, the predicted OS from the nomogram was also
similar to the OS from the control arms in the original studies, indicating good performance.
Interestingly, in the single-arm phase II STELLAR study [12], the OS estimate from the
nomogram was 16.95 months (95% CI: 10.49–27.38 months), compared to 18.2 months. The
OS reported in this study falls within the range of the 95% confidence interval predicted
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from the nomogram. This demonstrates the importance of patient numbers in phase II
trials, as the effectiveness of a phase II trial cannot be measured due to the wide confidence
interval, prompting well-powered confirmatory studies. A well-designed phase II trial with
complete reporting of the trial design, patient eligibility, study endpoints, and statistical
analyses may be reliable and applicable in rare diseases, such as MPM [32].
There are important limitations to our analysis that should be noted. Formally, any
categorical variable should have specific outcome-specific data to optimize the performance
of the meta-regression. For example, for gender, male-specific OS and female-specific OS
should be calculated. Unfortunately, this was difficult to extract from existing publications,
since this level of detail is seldom reported. Similarly, Brims et al. [33] developed a
prediction model for MPM using variables like Hb, weight loss, and albumin, which was
unable to be extracted from existing publications for this study but would likely improve
the performance of the survival estimates. However, in this study, we included percentages
as continuous variables in the meta-regression. Furthermore, individual patient-level data
can also be used to enhance any created model and should be pursued in subsequent
studies. Given this promising approach with study-level data, further projects using
individual patient-level data should be performed.
5. Conclusions
Given the rare incidence of MPM and the aggressive nature of the disease course,
innovative clinical trial designs with significantly weighted randomization to experimental
regimens can be utilized using robust survival estimates from prior studies. This study pro-
vides baseline comparative values and also allows for accounting for differing proportions
of known prognostic variables. Collaborative efforts can drive change in the right direction,
and appreciable progress has to be facilitated. Newer trial designs may be needed to pave
the way for future innovations in this rare disease.
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Appendix A
Table A1. Demographic data for patients with malignant pleural mesothelioma treated with experimental therapies, negative on phase II/III studies.









Sex [No.(%)] ECOG Performance Status [No.(%)] Tumour stage Tumour Pathology
Male Female 0 1 2 Locally Advanced Metastatic Epithelioid Biphasic Sarcomatoid
Nowak
et al. [34] 2002 NA NA II Cisplatin + Gemcitabine ORR PFS, OS, QoL 53 63 45 (85%) 8 (15%) 17 (32%) 31 (59%) 5 (9%) 33 (62%) 13 (25%) 42 (79%) 2 (4%) 7 (13%)
Van Haarst




II Cisplatin + Gemcitabine ORR PFS, OS, QoL 32 56 27 (86%) 5 (14%) 5 (14%) 26 (85%) 1 (1%) 15 (48%) 13 (41%) 26 (82%) 3 (9%) 3 (9%)
Favaretto




Toxicity 50 60 34 (68%) 16 (32%) 11 (22%) 33 (66%) 6 (12%) 11 (22%) 12 (24%) 34 (68%) 13 (26%) 3 (6%)
Schutte








2005 NA NA III Cisplatin + Raltitrexed OS PFS, RR, safety,QoL 126 59 104 (83%) 22 (17%) 32 (25%) 77 (61%) 17 (14%) NA NA 95 (75%) 18 (14%) 5 (4%)
Castagneto
et al. [39] 2005 NA 1999–2001 II Cisplatin + Gemcitabine ORR OS, PFS 35 61 21 (60%) 14 (40%) 33 (94%) 2 (6%) 8 (23%) 16 (46%) 22 (63%) 10 (29%) 3 (8%)
Fennell
et al. [40] 2005 NA NA II
Oxaliplatin +
Vinorelbine ORR OS, PFS 26 60 21 (87%) 5 (13%) 6 (16%) 15 (69%) 5 (13%) 6 (16%) 15 (79%) 13 (75%) 7 (18%) 5 (13%)
Berghmans
et al. [41] 2005 NA 1998–2003 II Cisplatin + Epirubicin ORR
Toxicity and
OS 69 62 59 (93%) 10 (7%) NA NA NA 18 (12%) 23 (19%) 43 (74%) 6 (10%) 9 (16)
Kalmadi
et al. [42] 2008 SWOG 9810 1999–2000 II Cisplatin + Gemcitabine OS ORR, Toxicity 50 69 44 (88%) 6 (12%) 13 (26%) 27 (54%) 10 (20%) NA NA 25 (50%) 3 (6%) 4 (8%)
Dowell
et al. [43] 2012 NA NA II
Cisplatin + Pemetrexed +
Bevacizumab PFS
RR, OS and
toxicity 52 66 44 (85%) 8 (15%) 17 (33%) 35 (67%) NA NA NA 32 (62%) 11 (21%) 7 (13%)
Kovac et al.
[44] 2012 NA 2002–2008 II Cisplatin + Gemcitabine RR
OS, PFS,
Toxicity 78 58 58 (74%) 20 (26%) 14 (18%) 51 (65%) 13 (17%) 38 (49%) 22 (29%) 56 (72%) 15 (19%) 4 (5%)
Kindler
et al. [45] 2012 NA 2001–2005 II
Cisplatin + Gemcitabine
+ Bevacizumab PFS OS 53 62 39 (73%) 14 (27%) 24 (45%) 29 (55%) NA NA NA 39 (74%) 14 (26%) NA
Ceresoli




PFS Toxicity, RRand OS 77 67 49 (64%) 27 (36%) 58 (76%) 18 (24%) NA NA NA 61 (80%) 6 (8%) 5 (7%)
O’Brien
et al. [47] 2013
EORTC
08052 2007–2010 II Cisplatin + Bortezomib PFSR-18
ORR, OS, PFS
and safety 82 55 55 (67%) 27 (33%) NA 73 (89%) NA 35 (43%) 28 (34%) 48 (59%) 11 (13%) 6 (7%)
Hassan






and safety 89 67 69 (78%) 20 (22%) NA NA NA 35 (39%) 43 (48%) 79 (89%) 10 (11%) NA
Krug et al.
[16] 2014 NA NA II
Cisplatin + Pemetrexed +
CBP50 PFS
OS, DCR, and
safety/toxicity 40 64 32 (80%) 8 (20%) 14 (35%) 25 (63%) 1 (3%) NA NA 30 (75%) 6 (15%) 4 (10%)
Buikhuisen
et al. [17] 2016 NA 2009–2012 II
Cisplatin + Pemetrexed +





Cisplatin + Pemetrexed +
Ceradinib PFS
OS, DCR, and
safety/toxicity 45 72 38 (84%) 7 (16%) NA NA NA NA NA 34 (76%) 11 (24%) NA
Scagliotti
et al. [19] 2019
LUME-
Meso 2016–2018 III
Cispatin + Pemetrexed +
Nintedinab PFS
OS, ORR, DCR,
QoL 229 66 165 (72%) 64 (28%) 99 (43%)
130
(57%) NA 89 (39%) 113 (49%) 220 (96%) 9 (4%) NA
Abbreviations: OS = overall survival; PFS = progression free survival; ORR = objective response rate; RR = response rate; TTP = time to progression; DCR = disease control rate; QoL = quality of life,
ECOG = Eastern Cooperative Oncology Group; NA = not available.
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2002 14.6 NA NA 6.1 16 0 4 (16%) 18 (72%) 3 (12%) 88 4 (13%) 2 (6%) 4 (13%) 1 (3%) 1 (3%) 2 (6%) 0 0 0 9 (29%)
Favaretto
et al. [36] 2003 15.1 8 4.5 9.2 26 0 13 (26%) 25 (50%) 12 (24%) 76 8 (16%) 12 (24%) 17 (34%) 0 0 0 0 0 0 0
Schutte




2005 11.4 5.2 2.1 5.3 24 2 (2%) 24 (26%) 58 (63%) NA 89 4 (3%) 9 (7%) 2 (2%) 2 (2%) 3 (2%) 15(12%) 2 (2%) NA NA 18 (14%)
Castagneto
et al. [39] 2005 13 NA NA 8 26 0 9 (26%) 14 (40%) 11 (31%) 66 8 (24%) 21 (61%) 18 (52%) NA 12 (35%) 2 (6%) NA NA NA 12 (35%)
Fennell
et al. [40] 2005 10.4 2.8 NA 7.8 23 0 6 (23%) 17 (65%) 3 (12%) 88 NA 5 (18%) NA NA 2 (6%)
4
(12%) NA NA NA 4 (12%)
Berghmans
et al. [41] 2005 13.3 6.6 NA NA 19 0 12 (19%) 25 (40%) 24 (38%) 59 NA 57 (84%) 2 (3%) 1 (2%) NA NA 1 (2%) 2 (3%) NA 17
Kalmadi
et al. [42] 2008 10 3 NA 6 12 1 (2%) 5 (10%) 25 (50%) 19 (38%) 62 12 (24%) 25 (50%) 16 (32%) NA 2 (4%)
12
(24%) 3 (6%) NA 1 (2%) 3 (6%)
Dowell
et al. [43] 2012 14.8 NA NA 6.9 40 NA NA 35% NA 35 1 (2%) 6 (11%) 2 (4%) NA 3 (6%) 4 (8%) NA NA NA 2 (4%)
Kovac
et al. [44] 2012 17 NA NA 8 50 4 (5%) 35 (45%) 35 (45%) 4 (5%) 95 2 (3%) 18 (23%) NA NA NA NA NA NA NA 1 (1%)
Kindler
et al. [45] 2012 15.6 9.1 4.8 6.9 25 0 13 (25%) 27 (51%) 12 (28%) 75 2 (4%) 22 (42%) 20 (38%) 12 (23%) NA NA
5
(10%) NA NA NA
Ceresoli
et al. [46] 2013 15.3 9.5 3.9 6.9 34 NA 24 (34%) 44 (58%) NA 92 3 (4%) 6 (8%) 2 (3%) 2 (3%) 2 (3%) 6 (8%) NA 1 (1%) NA 2 (3%)
O’Brien
et al. [47] 2013 13.5 7.5 NA 5 27 2 (2%) 21 (29%) 39 (49%) 16 (20%) 80 1 (1%) 1 (1%) 9 (11%) 5 (6%) 2 (2%)
15
(18%) 5 (6%) NA 1 (1%) 3 (3%)
Hassan
et al. [48] 2014 14.8 NA NA 6.1 33 0 33% 42% 8% 75 10 (11%) 15 (17%) 0% 2 (3%) 2 (3%)
9
(10%) 0 3 (4%) 0% 4 (5%)
Krug et al.
[16] 2014 13.3 NA NA 5.1 31 0 12 (31%) 15 (38%) NA 69 3 (8%) 2 (6%) NA 1 (3%) 1 (3%)
7
(18%) NA NA NA 3 (8%)
Buikhuisen
et al. [17] 2016 18.9 NA NA 5.8 36 NA 8 (36%) 9 (43%) NA 79 1 (5%) 9 (45%) 1 (5%) 1 (5%) 3 (15%) 0 NA 1 (5%) NA 2 (10%)
Tsao et al.
[18] 2019 10 NA NA 7.2 50 NA NA NA NA NA 1 (2%) 6 (13%) 4 (9%) 10 (22%) 2 (4%)
6
(13%) NA NA NA 4 (9%)
Scagliotti




(6%) NA 1 (1%) 12 (5%)
Abbreviations: OS = overall survival; PFS = progression free survival; yr. = year; ORR = objective response rate; QoL = quality of life; NA = not available; N = number.
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